After being ushered onto the inside lane at FDA, regulators hand Amryt a CRL for rare disease drug - Endpoints News

Amryt may have earned a priority review for its drug to treat rare cases of epidermolysis bullosa (EB), but they got handed a CRL for their trouble in any case. The biotech reported Monday morning that the agency is demanding “additional confirmatory evidence…

Amryt may have earned a priority review for its drug to treat rare cases of epidermolysis bullosa (EB), but they got handed a CRL for their trouble in any case. The biotech reported Monday morning t… [+764 chars]

full article...